Glaukos Corporation

GKOS

Held by 7 specialist biotech funds

High Convergence

7 funds opened new positions. Next phase2 readout (lufepirsen high dose): Dec 2025. Short interest: 7.9% of float.

Medical - DevicesCEO: Thomas William BurnsIPO: 2015Website ↗

Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.

Catalysts

Phase 3PositiveQ3 2009Open-Angle GlaucomaNCT00323284

Primary: Intraocular Pressure (Measured in mm Hg) Less or Equal to 21 mm Hg on no Topical Hypotensive Meds (12 months)Enrollment:240/240Sites: 31RANDOMIZED, SINGLE, TREATMENT

Phase 3PositiveQ2 2011riboflavin ophthalmic solutionProgressive KeratoconusNCT00647699

Primary: Mean Change From Baseline in Maximum Keratometry (Kmax) (baseline,12 months)Enrollment:147/147Sites: 10RANDOMIZED, TREATMENT

Phase 3PositiveQ4 2013GlaucomaNCT01052558

Primary: Proportion of subjects with 12 month diurnalIOP </= 21 mmHg without use of ocular hypotensive medications for >/= 4 weeks prior to 12 month visit. (12 months)Enrollment:164/164Sites: 22RANDOMIZED, TREATMENT

Phase 2PositiveQ3 2017Travoprost Intraocular Implant, high elutionGlaucoma Open-angleNCT02754596

Primary: IOP (mmHg) Change From Baseline at Week 12 (12 weeks)Enrollment:154/154Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 2PositiveQ1 2022TravoprostOpen Angle GlaucomaNCT04615403

Primary: Ocular Safety (12 Months)Enrollment:33/33Sites: 14NA, TREATMENT

Phase 3Q1 2024iDose TROpen Angle Glaucoma, Ocular HypertensionNCT06061718

Phase 2Q3 2025Progressive KeratoconusNCT05314738

Phase 2Q4 2025lufepirsen high dosePersistent Corneal Epithelial DefectNCT05966493

Primary: Achieve Corneal Re-epithelialization Including Durability (CRC) (End of Study: 28 Days after achieving re-epithelialization)Enrollment:Target 84Sites: 28RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2026GLK-321 low dose BIDDemodex BlepharitisNCT07400965

Primary: Percentage of study eyes with elimination of collarettes (6 weeks)Enrollment:Target 250Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q2 2027GLK-221 Ophthalmic SolutionKeratoconusNCT07400952

Primary: Mean change from baseline in maximum corneal curvature (16 weeks)Enrollment:Target 100Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2027Travoprost Intraocular ImplantGlaucoma, Open-AngleNCT06066645

Phase 2Q1 2028Gen 2 Travoprost Intracameral ImplantGlaucomaNCT07075718

Phase 3Q2 2028Gen 2 Travoprost Intracameral ImplantGlaucomaNCT07495852

Phase 3TBDriboflavin: 0.12% riboflavin ophthalmic solution with the KXL systemCorneal EctasiaNCT01643252

Primary: Mean change in maximum corneal curvature (Kmax) between the VibeX active treatment group and placebo control group (Baseline to 6 months)0RANDOMIZED, SINGLE, TREATMENT

Glaukos Corporation

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research